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Abstract
Background: We report the first multi-site rotavirus genotype analysis in Canada. Prior to this study, there was a
dearth of rotavirus G and P genotyping data in Canada. Publically funded universal rotavirus vaccination in Canada
started in 2011 and has been introduced by four provinces to date. Uptake of rotavirus vaccines in Canada prior to
2012 has been very limited. The aim of this study was to describe the genotypes of rotavirus strains circulating in
Canada prior to widespread implementation of rotavirus vaccine by genotyping samples collected from selected
paediatric hospitals. Secondly we identified rotavirus strains that differed genetically from those included in the
vaccines and which could affect vaccine effectiveness.
Methods: Stool specimens were collected by opportunity sampling of children with gastroenteritis who presented
to emergency departments. Samples were genotyped for G (VP7) genotypes and P (VP4) genotypes by
hemi-nested multiplex PCR methods. Phylogenetic analysis was carried out on Canadian G9 strains to investigate
their relationship to G9 strains that have circulated in other regions of the world.
Results: 348 samples were collected, of which 259 samples were rotavirus positive and genotyped. There were 34
rotavirus antigen immunoassay negative samples genotyped using PCR-based methods. Over the four rotavirus
seasons, 174 samples were G1P[8], 45 were G3P[8], 22 were G2P[4], 13 were G9P[8], 3 were G4P[8] and 2 were G9P
[4]. Sequence analysis showed that all Canadian G9 isolates are within lineage III.
Conclusions: Although a limited number of samples were obtained from a median of 4 centres during the 4 years
of the study, it appears that currently approved rotavirus vaccines are well matched to the rotavirus genotypes
identified at these hospitals. Further surveillance to monitor the emergence of rotavirus genotypes in Canada is
warranted.
Background
Group A rotaviruses are a major cause of acute gastro-
enteritis in children under five, causing an estimated
453,000 deaths worldwide annually [1,2]. In Canada, as
in other developed countries, mortality is rare, although
rotavirus infections are costly from both societal and
health care system perspectives. Recently published
research on children with gastroenteritis admitted
to Canadian paediatric hospitals found that rotavirus
infections require 1300–1800 tertiary care hospital days
annually [3]. Furthermore, rotavirus gastroenteritis
results in outpatient visits and nonmedical costs, such
as lost work days that have a substantial economic
cost [3-6].
The outer capsid of rotavirus is composed of two
major antigenic proteins, VP4 and VP7. These proteins
are the main determinants of viral serotype, and the
genes that code for these proteins represent the P and
G genotype of rotaviruses respectively. The VP4 and
VP7 proteins are also the main targets for protective
neutralizing antibodies, and are thus key antigens in
vaccine development [7-9]. To date, 27 G genotypes and
35 P genotypes have been reported, although only 11 G
genotypes and 12 P genotypes have been recovered
from humans [10-14]. G and P genotypes are also 2
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components of the 11-component genotyping system
proposed to classify rotaviruses [14]. Five combinations
of these genotypes, G1P[8], G2P[4], G3P[8], G4P[8] and
G9P[8] are responsible for the majority of rotavirus
infections worldwide. These are also the most common
genotypes in North America, where they represent more
than 85% of rotaviruses detected in human gastrointes-
tinal disease [12,15-18]. Studies that have analysed only
the G genotypes, also found that G1, G2, G3, G4 and G9
predominated in North America [19-21].
Two live oral rotavirus vaccines were licensed in
Canada. RotaTeqW, licensed in Canada in August 2006,
is a pentavalent bovine reassortant vaccine based on the
bovine rotavirus WC3 strain as a backbone, and each of
the 5 vaccine strains contains one serotype of the human
outer capsid proteins (G1, G2, G3, G4, or P[8] sero-
types). RotarixW, licensed in Canada in July 2007, is a
monovalent live-attenuated G1P[8]vaccine derived from
human rotavirus 89–12, containing the two most com-
mon outer capsid serotypes. Extensive phase III trials for
these vaccines showed high efficacy in protecting chil-
dren against rotavirus disease of any severity, for strains
with the same serotypes as contained in the respective
vaccine, and there was a significant degree of cross-
reactivity against many genotypes not contained in the
vaccines [22]. Vaccines have been shown to be very ef-
fective in the United States, although changes in anti-
genic properties of circulating strains, due to antigenic
drift or recombination, may challenge the effectiveness
of the vaccines in the future [23-28]. In 2008, the Na-
tional Advisory Committee for Immunization (NACI)
and the Canadian Paediatric Society recommended the
use of rotavirus vaccine in Canada [29,30]. Despite this,
the uptake of rotavirus vaccines in Canada has been very
limited. Prior to this study, there was very little data on
the incidence of rotavirus G and P genotypes in Canada.
During the period of this study, vaccination use in
Canada was very low, well below 5% of the eligible
population were getting rotavirus vaccines (personal
observations). Starting in 2012, only four of 13 provinces
and territories offered rotavirus vaccine as part of their
publicly funded immunization programs [31].
To survey the baseline prevalence of rotavirus geno-
types prior to the introduction of rotavirus vaccine we
collected specimens from inpatients at select paediatric
hospitals. We utilised reverse transcriptase polymerase
chain reaction (RT-PCR) followed by hemi-nested multi-
plex polymerase chain reaction methods for P and G
genotyping [13,28,32-34]. Selected rotavirus strains were
further characterised by phylogenetic analysis: in par-
ticular we focussed on the Canadian G9 strains, since
this genotype has emerged and spread worldwide in re-
cent years, and is not a specific component of either of
the current vaccines.
Methods
A total of 348 stool samples were collected from children
that presented with diarrhea with or without vomiting to
eight Canadian pediatric hospital emergency departments
that were part of the Canadian Immunization Monitoring
Program, Active (IMPACT) network [35] from 2007 to
2010. Five pediatric hospitals were included in the study
during the first year (2007: Edmonton, Winnipeg, Ottawa,
Quebec City, Halifax), three hospitals for the years 2008
and 2009 (Ottawa, Quebec City, Halifax) and six in
2010 (Vancouver, Saskatoon, Winnipeg, Toronto, Ottawa,
Halifax). The total number of specimens collected at the
sites were as follows: Ottawa, 128; Halifax, 90; Quebec
City, 63; Edmonton, 24; Vancouver, 20; Saskatoon, 11;
Winnipeg, 9; Toronto, 3.
The study was approved by the research ethics boards
of each hospital, in accordance with the Helsinki Dec-
laration on ethical principles for medical research in-
volving human subjects. Specimens were collected from
children under 5 years of age that presented with diar-
rhea with or without vomiting at emergency depart-
ments during 2007, 2008 and 2009 [6]. Research nurses
at the emergency department of each centre approached
parents or guardians of children presenting with acute
diarrhea and asked them to consent to rotavirus testing
on the child’s stool sample. In 2010 the samples were
from children under 16 years of age who were hospita-
lized for laboratory confirmed rotavirus infection at six
hospitals (Vancouver, Saskatoon, Winnipeg, Toronto,
Ottawa, Halifax).
At each hospital stool samples underwent testing for
rotavirus by enzyme immunoassay (Premier rotaclone
EIA kit, Meridian Bioscience), chromatographic im-
munoassay (bioMerieux Vikia Rota-Adeno, or Coris Bio-
concept Combi strip) or by electron microscopy (EM).
All specimens were then sent to the National Microbiol-
ogy Laboratory for further testing and genotyping.
Genomic RNA was extracted from the stool samples
using a Nuclisens Easymag magnetic silica extraction
method (Biomerieux, France). Hemi-nested multiplex PCR
assays were used to P and G genotype the extracted RNA
[32,36-40]. PCR products were initially designated to
genotype based on size comparison after direct vi-
sualization after electropheresis on agarose gels. During
the course of genotyping work we replaced a previously
described primer specific for P[8] genotypes, 1T-1 [36],
with the degenerate primer 1T-1DCDN since it was found
to be complementary to a wider range of P[8] strains. The
1T-1DCDN primer was designed with the sequence 5’
TCT ACT GGR TYR ACR TG 3’ using the primer 1T-1D
[38] as a model, and an alignment of the VP4 variable re-
gion using the Clustal W algorithm in MEGA 5.0 [41].
The alignment included sequences from 66 previously
untypable Canadian P[8] samples (determined by genetic
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distance after sequencing), one Canadian P[4] sample, and
15 P[8] reference strains. The 1T-1DCDN primer binds at
nt 340–356, a similar position, but one nucleotide shorter
than that of 1T-1 (nt 339–356).
The new 1T-1DCDN primer was compared with 1T-1
primer for genotyping using a panel of 65 Canadian
rotavirus samples that included 47 samples that were
sequence-positive for P[8], 4 specimens that were P[4]
genotype and 14 that were rotavirus negative. The panel
was representative in that it was composed of specimens
that came from 5 different sites in 2007, 3 sites in 2008
and 2 sites in 2009.
All strains that were positively genotyped by hemi-
nested multiplex PCR were confirmed by sequencing of
the VP4 and VP7 regions, using the Con3/Con2 and
Beg9/End9 primer sets, respectively [36,37], or a suitable
alternative. PCR products were purified using Montage
PCR Centrifugal Filter Devices (Millipore, USA) and
then cloned for sequencing in Top10 chemically compe-
tent E. coli cells (Invitrogen, USA) using Invitrogen
5’TopoTA cloning kits or sequenced directly. Sequen-
cing of plasmids was carried out by the Genomics Core
section of the National Microbiology Laboratory using
T3 and T7 plasmid-specific primers.
Phylogenetic analysis was used for confirmation of
genotypes and for further analysis of the ORFs of
Canadian G9 strains. The Canadian G9 ORF sequences
of the strains RVA/Human-wt/CAN/RT034-07/2007/
G9P[8] through to RVA/Human-wt/CAN/RT088-09/
2009/G9P[8] (GenBank Accession numbers JF964998-
JF965010) were aligned, along with reference strains.
Phylogenetic trees were constructed using the Clustal
W algorithm in MEGA 5.0 software package [41], using
the Maximum Likelihood method for phylogenetic
analysis, with 1000 bootstrap replicates. Lineage
designation was based on similarity to previously
defined lineage reference strains [42,43].
Results
Stool samples were collected from children with gastro-
enteritis at eight different Canadian hospital sites be-
tween 2007 and 2010 (Figure 1), although only two of
the sites were sampled in all four years, and three sites
were sampled in only one year. Of 348 specimens, 271
were genotyped. Amongst these, 12 samples exhibited
multiple genotypes, suggestive of mixed infections.
Therefore, 259 specimens (74%) were assigned to a sin-
gle G and P genotype (Table 1) and 77 were negative.
Of the 348 samples that were screened for rotavirus in
hospital, 246 (71%) were positive by antigen immuno-
assay, and 102 (29%) screened negative. Of the speci-
mens that had screened positive in hospital 237 (96%)
were positively P and G for genotyped by PCR. Of the
102 specimens that had screened negative by antigen im-
munoassay, 34 (33%) were also successfully P and G
genotyped for rotavirus. Twelve (4.4%) of the rotavirus-
positive samples were indeterminate since they were ap-
parently mixed infections with samples containing two
or more genotypes of rotavirus (Table 1). The mixed
samples included three instances of G1P[4] + P[8] , six
instances of G1P[8] + G2P[4] and one instance each of
G1 + G3P[8], G3P[4] + P[8] and G1 + G9P[8]. Of the 57
stool samples from 2010 that were positive locally for
rotavirus, 50 were successfully genotyped and confirmed
by sequencing.
Overall, the most common genotype encountered in
this study was G1P[8], being present in 67% of the speci-
mens, and it was also the most prevalent genotype at all
sites (Figure 1) and during all 4 years (Figure 2). The
other common genotypes were G3P[8] (18%) and G2
Figure 1 Map showing the 8 study sites in Canada (black dots). Above each site is a pie chart showing the relative prevalence of rotavirus
genotypes detected between the years 2007–2010. The limited Toronto data (available for 2010 only) is included with Ottawa. A pie chart to the
top right of the map indicates the cumulative prevalence of all genotypes in the study for all the years of study.
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P[4] (8.5%). At one site (Ottawa) during 2009 there was
a significantly higher incidence of G9P[8] and a lower
proportion of G1P[8] genotypes (Table 1; 95% CI, modi-
fied Wald method for proportions).
With the P[8] genotyping assay, we found that all 31
of the false negatives from the 1T-1 primer were picked
up as P[8] samples by the 1T-1DCDN primer. In this
panel (which was deliberately weighted with samples
that were not picked up by the 1T-1 primer), the 1T-
1DCDN primer had a sensitivity of 98% and a specificity
of 90%, whereas the 1T-1 primer had a sensitivity of only
60% and a specificity of 82%. Thus 1T-1DCDN can be
Table 1 Rotavirus identifications shown by genotype, year and surveillance site
City Year Negative G1P[8] G2P[4] G3P[8] G4P[8] G9P[8] G9P[4] Mixed
Vancouver 2010 3 9 3 5 0 0 0 0
Edmonton 2007 1 13 4 0 0 0 0 6
Saskatoon 2010 2 5 1 2 0 0 1 0
Winnipeg 2007 1 3 0 0 0 0 0 0
2010 1 2 1 1 0 0 0 0
Toronto 2010 0 3 0 0 0 0 0 0
Ottawa 2007 2 25 1 1 1 0 0 0
2008 27 16 3 4 0 0 0 1
2009 4 20 3 0 0 12 0 1
2010 1 3 1 2 0 0 0 0
Quebec City 2007 4 15 1 7 0 0 0 0
2008 12 7 1 0 0 0 0 0
2009 1 6 2 5 0 0 0 2
Halifax 2007 1 5 1 1 0 1 0 1
2008 5 29 0 0 0 0 0 0
2009 12 3 0 17 2 0 0 1
2010 0 10 0 0 0 0 1 0
Total 77 174 22 45 3 13 2 12
Figure 2 Genotype prevalence by year for all Canadian sites. The four seasons of surveillance are represented from left to right.
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usefully added to the panel for genotype screening tests,
and could potentially replace the 1T-1 primer.
A phylogenetic tree constructed with full VP7 gene
sequences from all of the Canadian G9P[8] isolates in-
cluding several prototype G9 sequences from different
regions of the world is shown in Figure 3. The tree shows
that the Canadian G9 isolates fall into the lineage III
major subcluster, being more similar to G9 sequences
from isolates obtained globally than to previously
sequenced minor subcluster lineage III isolates from Asia.
Discussion
Here we report the results of the first systematic, multi-
site and multi-season rotavirus genotyping study in
Canada. The most prevalent genotype found in children
with gastroenteritis at all the sites throughout the four
Figure 3 Phylogenetic tree of the VP7 genome segments of Canadian isolates of rotavirus along with selected G9 prototype
sequences. The maximum-likelihood tree was bootstrapped 1000 times. Canadian G9P[8] strains are represented in the tree. All Canadian strains
are designated with “RT” and their numbers end with the year of specimen collection.
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years of the study was G1P[8]. Other common genotypes
were G3P[8] and G2P[4]. Until the present study, only
two previous Canadian genotyping studies had been car-
ried out: these were restricted to G-genotyping only at
single sites during single seasons [19,21]. Our current
genotyping data indicate that the available vaccines
should be serologically well-matched to the prevalent
strains of rotavirus, based on the genotype prevalence at
these sites. Previous single-site studies in Canada during
1999 and 2002 also found G1 as the most prevalent
rotavirus genotype [19,21]. Although G1, G2, G3 and G4
are the main serotypes present in North America and
Europe, other serotypes are important causes of rota-
virus gastroenteritis worldwide, such as G5 in South
America and G8 in Africa [44-49]. G9 strains emerged
in the 1990s as a cause of a significant proportion of
rotavirus cases which varied regionally from 5 to 90%
[44,50-53]. Although we did not sample every site in
every year in the current study, our results provide re-
cent data on the occurrence of rotavirus genotypes in
Canada, during the period prior to vaccine roll-out. Our
sampling rate is equivalent to about 1 per 100,000 popu-
lation over the 4 years of the study in Canada, covering
a median of 4 centres. This sampling rate compares
favourably with other surveillance studies including one
carried out previously in the United States [48]. We cal-
culate that our study would have a 95% probability of
detecting a rotavirus genotype with an incidence of 1.5%
per year. Therefore, this level of sampling may miss any
rare genotypes that occur incidentally and which do not
spread in the population beyond one to two percent.
G9P[8] strains were identified in the current study but
were mostly restricted to single isolates in a few sites
during 2 seasons (2007 and 2010) rather than fully emer-
ging as a prevalent genotype. Recently, G9 genotypes
have also been identified in the United States and com-
prised 39% of the rotavirus genotypes indentified in
Detroit between 2007 and 2009 [41]. Since G9 was only
substantially present in one site and for one season in
Canada (Ottawa in 2009), and could therefore be a geno-
type that occurs with irregular frequency in Canada, we
decided to investigate the possible origins of these
strains using phylogenetic analysis. This shows that the
Canadian G9 rotavirus strains collected in the present
study are part of G9 lineage III (Figure 3). Although up
to six lineages of G9 have been described, most viruses
fall into three main lineages, I, II and III: a small number
of G9 strains that do not fit into these lineages have also
been reported [43]. The G9 genotype emerged world-
wide starting in about 1995, and appeared to spread
worldwide during the 2000s [43]. Sequence analysis indi-
cated that one particular subcluster of G9 lineage III
seemed to spread and cause disease throughout much of
the world [43]. Most of the circulating G9 rotaviruses
worldwide, including all of the G9 specimens from our
study, are in the major subcluster of lineage III [43].
Thus Canada can be added to the growing list of coun-
tries where this lineage has been identified. Lineage I
and II G9 rotaviruses are less common and were
detected primarily within the United States, Japan and
India in the 1980s and 90s, but reports of new lineages
circulating in other countries underline the importance
of continued rotavirus surveillance. [12,46,54-56].
Based on sequencing of a 981 bp region of the open
reading frame of VP7, the Canadian G9 strains are more
similar to isolates from Australia, Brazil and Italy than
the G9 strain found in Detroit designated MI08/USA
(Figure 3). Sequencing data from the two Canadian
2010 G9 strains also showed that they have between 96
and 98.5 percent identity with 2009 Canadian rotavirus
strains. In addition the 2010 strains are most similar to
the 2007 G9P[8] strain from Halifax, rather than the
2009 Ottawa strains (data not shown). Although G9 is
not present in either vaccine, there is serological cross
protection amongst G genotypes and amongst differing
P genotypes since the majority of these Canadian G9
viruses were G9P[8] and the P[8] antigenic component
is present in both vaccines. Given that two G9P[4]
strains were collected in 2010, surveillance of genotype
data is warranted to monitor genotype prevalence as
there is the possibility of an increase in the prevalence of
rarer genotypes, or genetic drift leading to immune es-
cape [28,44]. For example, emerging strains such as G12
have been detected in New York State [57] and in Italy
[58] and may spread to Canada in the future.
The local fluctuation of genotype prevalence that is
frequently seen from year to year in circulating rotavirus
was also demonstrated by less frequent genotypes such
as G3P[8], that was more prevalent in 2009 and
accounted for 77% of all rotavirus-positive samples from
Halifax. The high prevalence of G3P[8] in Halifax in
2009 was preceded and followed by seasons in which no
G3P[8] samples were detected at that site.
Conclusions
Hemi-nested multiplex PCR is a rapid method for geno-
typing rotavirus samples, based on highly conserved
genotype-specific regions [32,36,37]. Nevertheless, muta-
tions may cause mispairing resulting in an untypable
strain or a mistyping error [39]. Therefore we monitored
the primer-binding regions of isolates collected during
the study for genetic differences that could affect sensi-
tivity and specificity. The 1T-1DCDN primer was devel-
oped to genotype Canadian P[8] samples that have
mismatches in the binding region of the previously used
1T-1 primer, which failed to genotype many of the
Canadian P[8] isolates. The 1T-1DCDN primer was vali-
dated for specificity and sensitivity for genotyping
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unidentified Canadian P[8] samples as well as those pre-
viously identified with 1T-1, and thus may be useful in
future Canadian genotyping studies.
The finding of rotavirus in one third of samples which
were negative by antigen testing or EM in this study also
illustrates the lower sensitivity of antigen testing for
rotavirus. However, antigen detection tests may be less
prone to detecting low level background infections, and
are therefore useful for studies to measure the burden of
rotavirus illness, as well as for investigating the effective-
ness of vaccine in decreasing all-cause gastrointestinal
illness in the younger age groups. Our findings in this
study strongly suggest that currently licensed vaccines
are well matched to the rotavirus strains present in re-
cent years in Canada, and that continued surveillance is
warranted to monitor the situation after Canadian uni-
versal vaccination programs have been fully introduced.
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